BioSpace News Archive

Centogene N.V.(Nasdaq:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place at the Westin St. Francis, San Francisco, CA on January 9-12, 2023.

Avivagen Inc. announces that, pursuant to Policy 4.4 of the TSX Venture Exchange, it has entered into a “securities for services” agreement with each of Top Meadow Consulting Services Inc. and Mr. Graham Burton, pursuant to which the Company may elect to settle up to 15% of the fees or salary of such persons in common shares of the Company for the period from October 1, 2022 to February 28, 2023.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.

Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel).

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 867,130 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Intelligent Bio Solutions Inc. announced that it has closed a Regulation S private placement for expected aggregate gross proceeds of $220,585.

Celltrion USA announced the submission of a Biologics License Application under the 351 pathway of the Public Health Service Act for lead product candidate, CT-P13 SC, which is the subcutaneous formulation of infliximab to the U.S. Food and Drug Administration.

Mesoblast Limited announced that funds managed by Oaktree Capital Management, L.P. have extended to Mesoblast the availability of up to an additional US$30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023.